miptenalimab (BI 754111) / Boehringer Ingelheim 
Welcome,         Profile    Billing    Logout  
 0 Diseases   4 Trials   4 Trials   52 News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
miptenalimab (BI 754111) / Boehringer Ingelheim
2018-002344-81: Platform trial evaluating safety and efficacy of BI 754091 anti- PD-1 based combination therapies in PD-(L)1 naïve and PD- (L)1 pretreated patient populations with advanced/metastatic solid tumours

Not yet recruiting
2
260
Europe
BI 754091, BI 754111, BI 836880, BI 754091, BI 754111, BI 836880, Solution for infusion
Boehringer Ingelheim Limited, Boehringer Ingelheim
Advanced/metastatic solid tumours, Advanced solid tumours, Diseases [C] - Cancer [C04]
 
 
NCT03697304 / 2018-002344-81: Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours

Completed
2
212
Europe, Canada, US
BI 754091, ezabenlimab, BI 754111, BI 836880
Boehringer Ingelheim, Boehringer Ingelheim
Neoplasm Metastasis
12/24
12/24
NCT03156114: This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.

Completed
1
172
Europe, Canada, US
BI 754111, BI 754091
Boehringer Ingelheim
Neoplasms, Carcinoma, Non-Small-Cell Lung
03/23
06/23
NCT03433898: This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer

Completed
1
146
Japan, RoW
BI 754091, BI 754111
Boehringer Ingelheim
Neoplasms
07/23
07/23
NCT03964233: A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)

Active, not recruiting
1
120
Europe, Japan, US, RoW
BI 907828, Brigimadlin, ezabenlimab, BI 754091, BI 754111
Boehringer Ingelheim
Neoplasms
09/24
05/26

Download Options